Market Overview

UPDATE: Deutsche Bank Reiterates Buy Rating, Raises PT on XenoPort

Related XNPT
Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs
Jefferies Weighs In On Specialty Pharmaceuticals After Management Meetings, Raises Price Targets On 5 Stocks

In a report published Friday, Deutsche Bank reiterated its Buy rating on XenoPort (NASDAQ: XNPT), and raised its price target from $10.00 to $12.00.

Deutsche Bank noted, “Maintain Buy following positive initial clinical data for XP'829. XenoPort's transporter technology platform potentially offers a deep pipeline of opportunities, including XP'986 for spasticity, XP'829 (“BG12” like compound), and recently launched Regnite (Astellas) in Japan, etc. Hence, we continue to view XenoPort as an attractive investment opportunity despite the ongoing dispute over Horizant with GSK.”

XenoPort closed on Thursday at $11.15.

Latest Ratings for XNPT

Jan 2015JefferiesMaintainsBuy
Apr 2014JefferiesInitiates Coverage onBuy
Jun 2013Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for XNPT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (XNPT)

Around the Web, We're Loving...